<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2341-4545</journal-id>
<journal-title><![CDATA[GE-Portuguese Journal of Gastroenterology]]></journal-title>
<abbrev-journal-title><![CDATA[GE Port J Gastroenterol]]></abbrev-journal-title>
<issn>2341-4545</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Gastrenterologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2341-45452022000500041</article-id>
<article-id pub-id-type="doi">10.1159/000518945</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Inflammatory Bowel Disease Patients&#8217; Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Revés]]></surname>
<given-names><![CDATA[Joana Branco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Frias-Gomes]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morão]]></surname>
<given-names><![CDATA[Bárbara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nascimento]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palmela]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fidalgo]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Lídia Roque]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Glória]]></surname>
<given-names><![CDATA[Luísa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cravo]]></surname>
<given-names><![CDATA[Marília]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Beatriz Ângelo Surgical Department Gastroenterology Division]]></institution>
<addr-line><![CDATA[Loures ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Associação Portuguesa da Doença Inflamatória do Intestino (APDI)  ]]></institution>
<addr-line><![CDATA[Matosinhos ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade de Lisboa Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>10</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>10</month>
<year>2022</year>
</pub-date>
<volume>29</volume>
<numero>5</numero>
<fpage>41</fpage>
<lpage>49</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2341-45452022000500041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2341-45452022000500041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2341-45452022000500041&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Patients with inflammatory bowel disease (IBD) do not seem to be at increased risk of infection by SARS-CoV-2, but there is a concern whether immunosuppressive therapy may be associated with more severe disease. Several clinical practice recommendations have been published to help guide IBD care during the COVID-19 pandemic. Nonetheless, few studies have addressed patients&#8217; perspectives and fears. We aimed to evaluate Portuguese IBD patients&#8217; perspectives on the clinical management of their disease during the SARS-CoV-2 pandemic as well as the impact on their professional life.  Methods:  An anonymous electronic survey was created using REDCap and was distributed by the Portuguese Association of Inflammatory Bowel Disease (APDI) between May and August 2020. Patients&#8217; perspectives on immunosuppressive therapy, disease management, interaction with gastroenterology departments, and the impact of the pandemic in their professional life were assessed. Patients&#8217; proposals to improve medical care were also evaluated. Descriptive analysis and logistic regression were performed.  Results:  A total of 137 participants answered the survey (79.6% females, mean age 41.7 ± 12.1 years). Although having IBD and receiving treatment with immunosuppressors (thiopurines, steroids, or biologics) were considered promotors of anxiety, most patients (85.4%) agreed that disease remission was a priority and only a minority of patients interrupted their treatment during the pandemic. In multivariate analysis, active disease, biologic treatment, and use of corticosteroids in the last 3 months were perceived by the patients as high-risk features for increased risk of SARS-Cov-2 infection and more severe disease. Fifty-nine patients (44%) believed that their follow-up was influenced by the pandemic and only 58.8% felt that they had the opportunity to discuss their therapeutic options with their doctor. Sixty-three patients (46.0%) were working from home during the pandemic, although this decision was related to IBD and immunosuppressive therapy in only 36.5 and 39.7% of the cases, respectively. Areas where care could have been improved during the pandemic were identified by patients, namely enhancement of the communication with IBD professionals, conciliation of telemedicine with face-to-face appointments, and facilitation of the interaction between patients and employers.  Conclusion:  Most patients agreed that maintaining IBD remission is crucial, and only a minority of the patients stopped their treatment as per their own initiative. IBD status only had a small influence on patients&#8217; professional activity during the COVID-19 outbreak, with most changes being related to the pandemic itself.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  Os doentes com doença inflamatória do intestino (DII) não parecem ter um risco aumentado de infeção por SARS-CoV-2, mas existe receio de que a terapêutica imunossupressora possa estar associada a doença mais grave. Durante a pandemia COVID-19 foram publicadas recomendações clínicas para ajudar no seu tratamento, mas poucos estudos avaliaram as perspetivas e receios dos doentes. O presente estudo tem como objetivo avaliar as perspetivas dos doentes portugueses com DII relativamente à gestão da sua doença durante a pandemia e enfatizar a influência da COVID-19 na sua vida laboral.  Métodos:  Um inquérito anónimo eletrónico foi desenvolvido através do REDCap e divulgado pela Associação Portuguesa da Doença Inflamatória do Intestino (APDI) entre maio e agosto de 2020. Foram analisados dados relativos às perspetivas dos doentes sobre a terapêutica imunossupressora, gestão da doença, interação com os serviços de gastrenterologia e impacto da pandemia na vida laboral. As propostas dos doentes para melhorar a qualidade dos cuidados de saúde também foram avaliadas. Foi realizada uma análise estatística descritiva e regressão logística para avaliar fatores preditores.  Resultados:  Um total de 137 doentes responderam ao inquérito (79.6% do sexo feminino, com idade média de 41.7 ± 12.1 anos). Apesar de a DII e imunossupressão serem considerados fatores promotores de ansiedade, a maioria dos doentes (85.4%) concordou que a manutenção da remissão da doença é uma prioridade e apenas seis doentes interromperam a terapêutica durante a pandemia. Na análise multivariada, a presença de doença ativa, terapêutica com biológico e uso de corticoides nos últimos três meses foram considerados pelos doentes fatores preditores para um maior risco de infeção e maior gravidade da doença. Cinquenta e nove doentes (44%) consideraram que o seu seguimento clínico foi influenciado pela pandemia e apenas 58.8% considerou que teve a oportunidade de discutir as opções terapêuticas com o seu médico. Sessenta e três doentes (46%) estiveram em teletrabalho durante a pandemia, apesar de esta decisão ter estado relacionada com a DII e com a imunossupressão em apenas 36.5% e 39.7% dos casos, respetivamente. Foram identificadas áreas onde os cuidados prestados podem ser melhorados, incluindo, melhoria da comunicação com os especialistas de DII, conciliação da telemedicina com a medicina presencial e facilitação da interação entre doentes e empregadores.  Conclusão:  A maioria dos doentes concordou que a manutenção da remissão clínica é essencial e apenas uma minoria suspendeu a medicação por iniciativa própria. O estado da doença apenas teve uma pequena influência nas alterações laborais dos doentes com DII, tendo a maioria das decisões ocorrido como consequência direta da pandemia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Inflammatory bowel disease]]></kwd>
<kwd lng="en"><![CDATA[Crohn&#8217;s disease]]></kwd>
<kwd lng="en"><![CDATA[Ulcerative colitis]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="pt"><![CDATA[Doença inflamatória do intestino]]></kwd>
<kwd lng="pt"><![CDATA[Doença de Crohn]]></kwd>
<kwd lng="pt"><![CDATA[Colite ulcerosa]]></kwd>
<kwd lng="pt"><![CDATA[COVID-19]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Worldmeter</collab>
<source><![CDATA[]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ungaro]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gearry]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Kissous-Hunt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of IBD medications on COVID-19 outcomes results from an international registry]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2021</year>
<volume>70</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>725-32</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>D'Amico F.Rahier JF.Leone S.Peyrin-Biroulet L.Danese S</collab>
<article-title xml:lang=""><![CDATA[Views of patients with inflammatory bowel disease on the COVID-19 pandemic a global survey]]></article-title>
<source><![CDATA[Lancet Gastroenterol Hepatol]]></source>
<year>2020</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>631-2</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Berre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Peyrin-Biroulet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Buisson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olympie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ravel]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Bienenfeld]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of inflammatory bowel diseases on working life A French nationwide survey]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2019</year>
<volume>51</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>961-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rahier]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[MacMahon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory Bowel Disease Management During the COVID-19 Outbreak The Ten Do's and Don'ts from the ECCO-COVID Taskforce]]></article-title>
<collab>van der Woude CJ</collab>
<source><![CDATA[J Crohn's Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>14 Suppl 3</numero>
<issue>14 Suppl 3</issue>
<page-range>S798-806</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>GEDII</collab>
<source><![CDATA[DII na era COVID-19: o que muda na abordagem clínica à organização dos centros - a realidade Portuguesa]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Rai]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahuja]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Allez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Organization for the Study of Inflammatory Bowel Disease. Management of Patients with Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting.]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2020</year>
<volume>159</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Walls]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gollins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buisson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olympie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease]]></article-title>
<collab>BIOCYCLE group</collab>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2021</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>403-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perisetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goyal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful Distancing Telemedicine in Gastroenterology and Hepatology During the COVID-19 Pandemic]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2021</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>945-53</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<source><![CDATA[IBDcoach]]></source>
<year>10/0</year>
<month>5/</month>
<day>20</day>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<source><![CDATA[HealthPROMISE]]></source>
<year>10/0</year>
<month>5/</month>
<day>20</day>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kobold]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Bootsman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dijkstra]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[van Rheenen]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity.]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>15</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1742-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lees]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Regueiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadevan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Organization for the Study of Inflammatory Bowel Disease Global Strategies for Telemedicine and Inflammatory Bowel Diseases]]></article-title>
<source><![CDATA[J Crohn's Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>14 Suppl 3</numero>
<issue>14 Suppl 3</issue>
<page-range>S780-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
